Athira Pharma (ATHA) Competitors $0.39 +0.02 (+5.95%) Closing price 04:00 PM EasternExtended Trading$0.39 -0.01 (-1.28%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. CELU, ASRT, INCR, IRD, GNTA, ATRA, IMA, BMEA, OTLK, and APLTShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Celularity (CELU), Assertio (ASRT), InterCure (INCR), Opus Genetics (IRD), Genenta Science (GNTA), Atara Biotherapeutics (ATRA), Ikena Oncology (IMA), Biomea Fusion (BMEA), Oncobiologics (OTLK), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors Celularity Assertio InterCure Opus Genetics Genenta Science Atara Biotherapeutics Ikena Oncology Biomea Fusion Oncobiologics Applied Therapeutics Celularity (NASDAQ:CELU) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Which has higher earnings and valuation, CELU or ATHA? Celularity has higher revenue and earnings than Athira Pharma. Celularity is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$54.22M1.43-$57.89M-$2.65-1.22Athira PharmaN/AN/A-$96.94M-$2.07-0.19 Does the media refer more to CELU or ATHA? In the previous week, Celularity and Celularity both had 2 articles in the media. Athira Pharma's average media sentiment score of 0.63 beat Celularity's score of 0.00 indicating that Athira Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Athira Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CELU or ATHA? 19.0% of Celularity shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 22.1% of Celularity shares are held by company insiders. Comparatively, 22.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CELU or ATHA more profitable? Athira Pharma has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Athira Pharma's return on equity of -142.99% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-106.77% -271.88% -42.82% Athira Pharma N/A -142.99%-106.40% Do analysts prefer CELU or ATHA? Athira Pharma has a consensus price target of $11.25, indicating a potential upside of 2,769.90%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, CELU or ATHA? Celularity has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500. SummaryAthira Pharma beats Celularity on 9 of the 12 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.30M$2.98B$5.45B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-0.1917.8930.0425.01Price / SalesN/A174.35377.6078.24Price / CashN/A41.8335.9458.58Price / Book0.347.278.135.68Net Income-$96.94M-$54.43M$3.25B$265.58M7 Day Performance5.89%-0.07%1.09%2.50%1 Month Performance5.95%5.07%2.75%1.87%1 Year Performance-87.23%10.31%28.40%24.05% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma3.781 of 5 stars$0.39+5.9%$11.25+2,769.9%-88.1%$15.30MN/A-0.1940News CoverageEarnings ReportGap UpCELUCelularity0.074 of 5 stars$3.29+11.1%N/A+17.3%$70.89M$54.22M-1.24220Upcoming EarningsASRTAssertio1.85 of 5 stars$0.73-2.0%$2.63+262.1%-41.1%$70.88M$124.96M-2.2720News CoverageUpcoming EarningsINCRInterCureN/A$1.51-2.6%N/A-26.8%$70.64M$66.28M0.00350News CoverageIRDOpus Genetics1.3163 of 5 stars$1.20+1.7%$7.33+511.1%N/A$70.40M$10.99M-0.5714Upcoming EarningsGap UpGNTAGenenta Science2.6001 of 5 stars$3.75-0.8%$25.00+566.5%-15.7%$69.14MN/A0.007News CoveragePositive NewsShort Interest ↑ATRAAtara Biotherapeutics3.825 of 5 stars$11.81+2.0%$20.00+69.3%+46.9%$69.03M$128.94M-3.17330Upcoming EarningsIMAIkena Oncology3.4617 of 5 stars$1.48+8.0%$35.50+2,298.6%-24.8%$69.01M$9.16M-2.31780Upcoming EarningsBMEABiomea Fusion3.6885 of 5 stars$1.80-1.6%$20.10+1,016.7%-71.8%$68.76MN/A-0.5150News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionOTLKOncobiologics2.4313 of 5 stars$2.01-1.5%$9.60+377.6%-73.8%$68.48MN/A-2.2120News CoverageUpcoming EarningsGap UpAPLTApplied Therapeutics4.0842 of 5 stars$0.49+2.1%$6.10+1,144.9%-93.0%$67.96M$460K-1.1430 Related Companies and Tools Related Companies CELU Competitors ASRT Competitors INCR Competitors IRD Competitors GNTA Competitors ATRA Competitors IMA Competitors BMEA Competitors OTLK Competitors APLT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
